Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M115,429Revenue (TTM) $M37,728Net Margin (%)13.6Altman Z-Score2.0
Enterprise Value $M124,725EPS (TTM) $2.0Operating Margin %18.8Piotroski F-Score7
P/E(ttm)22.9Beneish M-Score-2.6Pre-tax Margin (%)16.4Higher ROA y-yY
Price/Book1.910-y EBITDA Growth Rate %-1.6Quick Ratio1.2Cash flow > EarningsY
Price/Sales3.15-y EBITDA Growth Rate %-4.2Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow17.7y-y EBITDA Growth Rate %-4.3ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %3.7PEG--ROE % (ttm)8.3Less Shares Outstanding y-yY
Payout Ratio %86.0Shares Outstanding M2,584ROIC % (ttm)7.6Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SNY is held by these investors:



SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-52.98view
Sanofi10% Owner 2015-01-26Buy647,448$95-52.98view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-52.06view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-33.21view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67482.4view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about sny:

    Articles On GuruFocus.com
    Award-Winning International Fund Manager David Herro Picks 3 Stocks Mar 03 2017 
    While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
    David Herro's Oakmark International Fund Fourth Quarter Letter Jan 11 2017 
    Something Strange Is Going On With Oral Insulin Dec 23 2016 
    Dodge & Cox Invests in 7 Positions in the 3rd Quarter Dec 19 2016 
    Warren Buffett’s Only Dividend Stocks With 4%-Plus Yields Nov 29 2016 
    World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
    First Eagle Investments Comments on Sanofi Oct 24 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 

    More From Other Websites
    Will Sanofi (SNY) Prove to be a Suitable Value Stock? Mar 22 2017
    Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help... Mar 22 2017
    Sanofi and Regeneron Sue Amgen over Eczema Drug Mar 21 2017
    Sanofi-Genzyme files preemptive legal strike to protect eczema drug Mar 21 2017
    Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims Mar 21 2017
    Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of... Mar 21 2017
    Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks Mar 21 2017
    [$$] Sanofi's Prescription for Growth: Drug Sales in the Middle Kingdom Mar 21 2017
    Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop Mar 20 2017
    Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing Mar 17 2017
    Amgen's Repatha Reduced Heart Attack, Stroke Risk Mar 17 2017
    The Zacks Analyst Blog Highlights: U.S. Bancorp, Verizon, EOG Resources, Sanofi and Nokia Mar 17 2017
    What are Sanofi's (SNY) Strengths and Challenges in 2017? Mar 17 2017
    New Stock Research Reports for Verizon, EOG, and U.S. Bancorp Mar 16 2017
    Sanofi, Regeneron’s Dupilumab Gets UK Early Access Mar 15 2017
    Bernie Sanders Slams Sanofi Zika Vaccine Deal Mar 15 2017
    Sanofi and Voluntis Ink Global Pact for Diabetes Mar 15 2017
    Amgen's Repatha Meets Primary Endpoint in Phase III Study Mar 14 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)